Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics Inc (NQ: ATOS )

0.9580 +0.0505 (+5.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,105,391
Open 0.9200
Bid (Size) 0.9300 (100)
Ask (Size) 0.9400 (17)
Prev. Close 0.9075
Today's Range 0.8800 - 0.9699
52wk Range 0.8351 - 9.800
Shares Outstanding 126,624,110
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
61 Biggest Movers From Yesterday
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga

Performance

YTD
-44.94%
-44.94%
1 Month
-7.88%
-7.88%
3 Month
-21.48%
-21.48%
6 Month
-55.44%
-55.44%
1 Year
-70.25%
-70.25%

More News

Read More
Analyzing Atossa Therapeutics's Unusual Options Activity
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ATOS Stock Holders Should Mark Their Calendars for Oct. 7
Via InvestorPlace
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden
Via Benzinga
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress
Via InvestorPlace
Atossa Therapeutics Has a Steep Climb Ahead of It
Via InvestorPlace
Exposures COVID-19
As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock
Via InvestorPlace
Exposures COVID-19
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now
Via InvestorPlace
With Zero Revenue, I Can’t Get Excited About Atossa
Via InvestorPlace
Exposures COVID-19
The Bear Case for Atossa Therapeutics Makes More Sense at This Time
Via InvestorPlace
Most Active Equity Options For Midday - Wednesday, Aug. 4
Via Talk Markets
88 Biggest Movers From Yesterday
Via Benzinga
Investors Should Avoid High-Risk Atossa Therapeutics
Via InvestorPlace
63 Biggest Movers From Friday
Via Benzinga
Exposures Product Safety
The Week In Charts: Trading Stuff Part 3 - Trading (Or Not Trading!) OGRes, Russian Dolls, ETFs
Via Talk Markets
ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
41 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Exposures Product Safety
20 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
Exposures Product Safety
Understanding Atossa Therapeutics's Unusual Options Activity
Via Benzinga
Wait for Atossa Therapeutics Stock to Slide Further Before Buying
Via InvestorPlace
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.